Advertisement

Drugs

pp 1–18 | Cite as

Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke

  • Andrea SantamatoEmail author
  • Nicoletta Cinone
  • Francesco Panza
  • Sara Letizia
  • Luigi Santoro
  • Madia Lozupone
  • Antonio Daniele
  • Alessandro Picelli
  • Alessio Baricich
  • Domenico Intiso
  • Maurizio Ranieri
Review Article
  • 65 Downloads

Abstract

Post-stroke lower limb spasticity impairs balance and gait leading to reduced walking speed, often increasing wheelchair use and caregiver burden. Several studies have shown that appropriate treatments for lower limb spasticity after stroke include injections of botulinum toxin type A (BoNT-A), phenol or alcohol, surgical correction and a rehabilitation program. In the present article, we review the safety and effectiveness of BoNT-A for the treatment of lower limb spasticity after stroke, with a focus on higher doses of BoNT-A. The cumulative body of evidence coming from the randomized clinical trials and open-label studies selected in the article suggest BoNT-A to be safe and efficacious in reducing lower limb spasticity after stroke. Studies of high doses of BoNT-A also showed a greater reduction of severe post-stroke spasticity. In stroke survivors with spasticity of the ankle plantar-flexor muscles, a combined approach between surgery and BoNT-A can be indicated. However, controversy remains about improvement in motor function relative to post-stroke spasticity reduction after BoNT-A treatment.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used to assist in the preparation of this study.

Conflicts of interest

Andrea Santamato, Nicoletta Cinone, Francesco Panza, Sara Letizia, Luigi Santoro, Madia Lozupone, Antonio Daniele, Alessandro Picelli, Alessio Baricich, Domenico Intiso, and Maurizio Ranieri have no conflicts of interest that are directly relevant to the content of this study.

References

  1. 1.
    Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, Simpson LL, So Y. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1691–8.Google Scholar
  2. 2.
    Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, Schnider P, Altavista MC, Cavazza S, Deltombe T, Duarte E, Geurts AC, Gracies JM, Haboubi NH, Juan FJ, Kasch H, Katterer C, Kirazli Y, Manganotti P, Parman Y, Paternostro-Sluga T, Petropoulou K, Prempeh R, Rousseaux M, Slawek J. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41:13–25.CrossRefGoogle Scholar
  3. 3.
    Sheean GL. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? Curr Opin Neurol. 2001;14:771–6.CrossRefGoogle Scholar
  4. 4.
    Deltombe T, Wautier D, De Cloedt P, Fostier M, Gustin T. Assessment and treatment of spastic equinovarus foot after stroke: guidance from the Mont-Godinne interdisciplinary group. J Rehabil Med. 2017;49:461–8.CrossRefGoogle Scholar
  5. 5.
    Ward AB. Managing spastic foot drop after stroke. Eur J Neurol. 2014;21:1053–4.CrossRefGoogle Scholar
  6. 6.
    Boudarham J, Hameau S, Pradon D, Bensmail D, Roche N, Zory R. Changes in electromyographic activity after botulinum toxin injection of the rectus femoris in patients with hemiparesis walking with a stiff-knee gait. J Electromyogr Kinesiol. 2013;23:1036–43.CrossRefGoogle Scholar
  7. 7.
    Carda S, Bertoni M, Zerbinati P, Rossini M, Magoni L, Molteni F. Gait changes after tendon functional surgery for equinovarus foot in patients with stroke: assessment of temporo-spatial, kinetic, and kinematic parameters in 177 patients. Am J Phys Med Rehabil. 2009;88:292–301.CrossRefGoogle Scholar
  8. 8.
    Farina S, Migliorini C, Gandolfi M, Bertolasi L, Casarotto M, Manganotti P, Fiaschi A. Smania N Combined effects of botulinum toxin and casting treatments on lower limb spasticity after stroke. Funct Neurol. 2008;23:87–91.PubMedGoogle Scholar
  9. 9.
    Carda S, Invernizzi M, Baricich A, Cisari C. Casting, taping or stretching after botulinum toxin type A for spastic equinus foot: a single-blind randomized trial on adult stroke patients. Clin Rehabil. 2011;25:1119–27.CrossRefGoogle Scholar
  10. 10.
    Baricich A, Carda S, Bertoni M, Maderna L, Cisari C. A single-blinded, randomized pilot study of botulinum toxin type A combined with non-pharmacological treatment for spastic foot. J Rehabil Med. 2008;40:870–2.CrossRefGoogle Scholar
  11. 11.
    Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54:743–9.CrossRefGoogle Scholar
  12. 12.
    Slavinski J, Pradon D, Bensmail D, Roche N, Zory R. Energy cost of obstacle crossing in stroke patients. Am J Phys Med Rehab. 2014;93:1044–50.CrossRefGoogle Scholar
  13. 13.
    Podsiadlo D, Richardson S. The timed up and go: a test of basic functional mobility for frail elderly persons. J Am Geriat Soc. 1991;39:142–8.CrossRefGoogle Scholar
  14. 14.
    Das TK, Park DM. Effect of treatment with botulinum toxin on spasticity. Postgrad Med J. 1989;65:208–10.CrossRefGoogle Scholar
  15. 15.
    Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86:1818–26.CrossRefGoogle Scholar
  16. 16.
    Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA. 2011;305:89–90.CrossRefGoogle Scholar
  17. 17.
    Santamato A, Panza F. Benefits and risks of non-approved injection regimens for botulinum toxins in spasticity. Drugs. 2017;77:1413–22.CrossRefGoogle Scholar
  18. 18.
    Dressler D, Mander GJ, Fink K. Equivalent potency of Xeomin® and Botox®. Mov Disord. 2008;1(23 suppl):S20–1.Google Scholar
  19. 19.
    Dressler D, Mander G, Fink K. Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay. J Neural Transm. 2012;119:13–5.CrossRefGoogle Scholar
  20. 20.
    Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, Marttila RJ, Lundh H, Gedin S, Westergren I, Richardson A, Dott C, Cohen H. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64:6–12.CrossRefGoogle Scholar
  21. 21.
    Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs RD. 2010;10:67–73.CrossRefGoogle Scholar
  22. 22.
    Wein T, Esquenazi A, Jost WH, Ward AB, Pan G, Dimitrova R. OnabotulinumtoxinA for the treatment of post-stroke distal lower-limb spasticity: a randomized trial. PM R. 2018.  https://doi.org/10.1016/j.pmrj.2017.12.006 (Epub ahead of print).
  23. 23.
    Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, Khatkova S, Benetin J, Vecchio M, McAllister P, Ilkowski J, Ochudlo S, Catus F, Grandoulier AS, Vilain C, Picaut P. International AbobotulinumtoxinA adult lower limb spasticity study group. efficacy and safety of abobotulinumtoxinA in spastic lower limb: randomized trial and extension. Neurology. 2017;89:2245–53.Google Scholar
  24. 24.
    Pittock SJ, Moore AP, Hardiman O, Ehler E, Kovac M, Bojakowski J, Al Khawaja I, Brozman M, Kanovský P, Skorometz A, Slawek J, Reichel G, Stenner A, Timerbaeva S, Stelmasiak Z, Zifko UA, Bhakta B, Coxon E. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis. 2003;15:289–300.CrossRefGoogle Scholar
  25. 25.
    Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol. 2010;257:1330–7.CrossRefGoogle Scholar
  26. 26.
    Burbaud P, Wiart L, Dubos JL, Gaujard E, Debelleix X, Joseph PA, Mazaux JM, Bioulac B, Barat M, Lagueny A. A randomised, double blind, placebo-controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry. 1996;61:265–9.CrossRefGoogle Scholar
  27. 27.
    Johnson CA, Burridge JH, Strike PW, Wood DE, Swain ID. The effect of combined use of botulinum toxin type A and functional electric stimulation in the treatment of spastic drop foot after stroke: a preliminary investigation. Arch Phys Med Rehabil. 2004;85:902–9.CrossRefGoogle Scholar
  28. 28.
    Dunne JW, Gracies JM, Hayes M, Zeman B, Singer BJ, Multicentre Study Group. A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke. Clin Rehabil. 2012;26:787–97.Google Scholar
  29. 29.
    Hesse S, Lücke D, Malezic M, Bertelt C, Friedrich H, Gregoric M, Mauritz KH. Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry. 1994;57:1321–4.CrossRefGoogle Scholar
  30. 30.
    Santamato A, Micello MF, Panza F, Fortunato F, Pilotto A, Giustini A, Testa A, Fiore P, Ranieri M, Spidalieri R. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study. Eur J Phys Rehabil Med. 2013;49:483–9.PubMedGoogle Scholar
  31. 31.
    Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci. 2005;26:26–31.CrossRefGoogle Scholar
  32. 32.
    Pimentel LH, Alencar FJ, Rodrigues LR, Sousa FC, Teles JB. Effects of botulinum toxin type A for spastic foot in post-stroke patients enrolled in a rehabilitation program. Arq Neuropsiquiatr. 2014;72:28–32.CrossRefGoogle Scholar
  33. 33.
    Picelli A, Bonetti P, Fontana C, Barausse M, Dambruoso F, Gajofatto F, Girardi P, Manca M, Gimigliano R, Smania N. Is spastic muscle echo intensity related to the response to botulinum toxin type A in patients with stroke? A cohort study. Arch Phys Med Rehabil. 2012;93:1253–8.CrossRefGoogle Scholar
  34. 34.
    Picelli A, Tamburin S, Bonetti P, Fontana C, Barausse M, Dambruoso F, Gajofatto F, Santilli V, Smania N. Botulinum toxin type A injection into the gastrocnemius muscle for spastic equinus in adults with stroke: a randomized controlled trial comparing manual needle placement, electrical stimulation and ultrasonography-guided injection techniques. Am J Phys Med Rehabil. 2012;91:957–64.CrossRefGoogle Scholar
  35. 35.
    Tok F, Balaban B, Yaşar E, Alaca R, Tan AK. The effects of onabotulinum toxin A injection into rectus femoris muscle in hemiplegic stroke patients with stiff-knee gait: a placebo-controlled, nonrandomized trial. Am J Phys Med Rehabil. 2012;91:321–6.CrossRefGoogle Scholar
  36. 36.
    Roche N, Boudarham J, Hardy A, Bonnyaud C, Bensmail B. Use of gait parameters to predict the effectiveness of botulinum toxin injection in the spastic rectus femoris muscle of stroke patients with stiff knee gait. Eur J Phys Rehabil Med. 2015;51:361–70.PubMedGoogle Scholar
  37. 37.
    Hameau S, Bensmail D, Robertson J, Boudarham J, Roche N, Zory R. Isokinetic assessment of the effects of botulinum toxin injection on spasticity and voluntary strength in patients with spastic hemiparesis. Eur J Phys Rehabil Med. 2014;50:515–23.PubMedGoogle Scholar
  38. 38.
    Riley PO, Kerrigan DC. Torque action of two-joint muscles in the swing period of stiff-legged gait: a forward dynamic model analysis. J Biomech. 1998;31:835–40.CrossRefGoogle Scholar
  39. 39.
    Sung DH, Bang HJ. Motor branch block of the rectus femoris: its effectiveness in stiff-legged gait in spastic paresis. Arch Phys Med Rehabil. 2000;81:910–5.CrossRefGoogle Scholar
  40. 40.
    Goldberg SR, Anderson FC, Pandy MG, Delp SL. Muscles that influence knee flexion velocity in double support: implications for stiff knee gait. J Biomech. 2004;37:1189–96.CrossRefGoogle Scholar
  41. 41.
    Caty GD, Detrembleur C, Bleyenheuft C, Deltombe T, Lejeune TM. Effect of simultaneous botulinum toxin injections into several muscles on impairment, activity, participation, and quality of life among stroke patients presenting with a stiff knee gait. Stroke. 2008;39:2803–8.CrossRefGoogle Scholar
  42. 42.
    Rousseaux M, Daveluy W, Kozlowski O, Allart E. Onabotulinumtoxin-A injection for disabling lower limb flexion in hemiplegic patients. NeuroRehabilitation. 2014;35:25–30.PubMedGoogle Scholar
  43. 43.
    Yelnik AP, Colle FM, Bonan IV, Lamotte DR. Disabling overactivity of the extensor hallucis longus after stroke: clinical expression and efficacy of botulinum toxin type A. Arch Phys Med Rehabil. 2003;84:147–9.CrossRefGoogle Scholar
  44. 44.
    Suputtitada A. Local botulinum toxin type A injections in the treatment of spastic toes. Am J Phys Med Rehabil. 2002;81:770–5.CrossRefGoogle Scholar
  45. 45.
    Royal College of Physicians. Guidance to good practice. Guidelines for the use of botulinum toxin (BTX) in the management of spasticity in adults. London: Royal College of Physicians; 2002.Google Scholar
  46. 46.
    Baricich A, Picelli A, Santamato A, Carda S, de Sire A, Smania N, Cisari C, Invernizzi M. Safety profile of high-dose botulinum toxin type A in post-stroke spasticity treatment. Clin Drug Investig. 2018.  https://doi.org/10.1007/s40261-018-0701-x (Epub ahead of print).
  47. 47.
    Baricich A, Grana E, Carda S, Santamato A, Cisari C, Invernizzi M. High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis. J Neural Transm (Vienna). 2015;122:1283–7.CrossRefGoogle Scholar
  48. 48.
    Hesse S, Jahnke MT, Luecke D, Mauritz KH. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett. 1995;201:37–40.CrossRefGoogle Scholar
  49. 49.
    Santamato A, Panza F, Ranieri M, Frisardi V, Micello MF, Filoni S, Fortunato F, Intiso D, Basciani M, Logroscino G, Fiore P. Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. J Neural Transm. 2013;120:469–76.CrossRefGoogle Scholar
  50. 50.
    Santamato A, Panza F, Intiso D, Baricich A, Picelli A, Smania N, Fortunato F, Seripa D, Fiore P, Ranieri M. Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke. J Neurol Sci. 2017;378:182–6.CrossRefGoogle Scholar
  51. 51.
    Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013;28:1775–83.CrossRefGoogle Scholar
  52. 52.
    Bhatia KP, Münchau A, Thompson PD, Houser M, Chauhan VS, Hutchinson M, Shapira AH, Marsden CD. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry. 1999;67:90–3.CrossRefGoogle Scholar
  53. 53.
    Baizabal-Carvallo JF, Jankovic J, Pappert E. Flu-like symptoms following botulinum toxin therapy. Toxicon. 2011;58:1–7.CrossRefGoogle Scholar
  54. 54.
    Roche N, Schnitzler A, Genet FF, Durand MC, Bensmail D. Undesirable distant effects following botulinum toxin type A injection. Clin Neuropharmacol. 2008;31:272280.CrossRefGoogle Scholar
  55. 55.
    Pickett A. Dysport: pharmacological properties and factors that influence toxin action. Toxicon. 2009;54:683–9.CrossRefGoogle Scholar
  56. 56.
    Ward AB, Wissel J, Borg J, Ertzgaard P, Herrmann C, Kulkarni J, Lindgren K, Reuter I, Sakel M, Säterö P, Sharma S, Wein T, Wright N, Fulford-Smith A. Functional goal achievement in post-stroke spasticity patients: the BOTOX® Economic Spasticity Trial (BEST). J Rehabil Med. 2014;46:504–13.CrossRefGoogle Scholar
  57. 57.
    Leach E, Cornwell P, Fleming J, Haines T. Patient centered goal-setting in a subacute rehabilitation setting. Disabil Rehabil. 2010;32:159–72.CrossRefGoogle Scholar
  58. 58.
    Sunnerhagen KS, Francisco GE. Enhancing patient–provider communication for long-term post-stroke spasticity management. Acta Neurol Scand. 2013;128:305–10.PubMedGoogle Scholar
  59. 59.
    Baricich A, Cosenza L, Sandrini G, Paolucci S, Morone G, Santamato A, Baricich A, Cosenza L, Sandrini G, Paolucci S, Morone G, Santamato A. Development of a patient-centered questionnaire for post-stroke spasticity assessment: a reliability study. Funct Neurol. 2018;33:113–5.Google Scholar
  60. 60.
    Rosales RL, Kong KH, Goh KJ, Kumthornthip W, Mok VC, Delgado-De Los Santos MM, Chua KS, Abdullah SJ, Zakine B, Maisonobe P, Magis A,Wong KS. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. Neurorehabil Neural Repair. 2012;26:812–21.Google Scholar
  61. 61.
    Fietzek UM, Kossmehl P, Schelosky L, Ebersbach G, Wissel J. Early botulinum toxin treatment for spastic pes equinovarus—a randomized double-blind placebo-controlled study. Eur J Neurol. 2014;21:1089–95.CrossRefGoogle Scholar
  62. 62.
    Tao W, Yan D, Li JH, Shi ZH. Gait improvement by low-dose botulinum toxin A injection treatment of the lower limbs in subacute stroke patients. J Phys Ther Sci. 2015;27:759–62.CrossRefGoogle Scholar
  63. 63.
    Kirazli Y, On AY, Kismali B, Aksit R. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil. 1998;77:510–5.CrossRefGoogle Scholar
  64. 64.
    Rousseaux M, Buisset N, Daveluy W, Kozlowski O, Blond SM. Comparison of botulinum toxin injection and neurotomy in patients with distal lower limb spasticity. Eur J Neurol. 2008;15:506–11.CrossRefGoogle Scholar
  65. 65.
    Bollens B, Gustin T, Stoquart G, Detrembleur C, Lejeune T, Deltombe T. A randomized controlled trial of selective neurotomy versus botulinum toxin for spastic equinovarus foot after stroke. Neurorehabil Neural Repair. 2013;27:695–703.CrossRefGoogle Scholar
  66. 66.
    Picelli A, Dambruoso F, Bronzato M, Barausse M, Gandolfi M, Smania N. Efficacy of therapeutic ultrasound and transcutaneous electrical nerve stimulation compared with botulinum toxin type A in the treatment of spastic equinus in adults with chronic stroke: a pilot randomized controlled trial. Top Stroke Rehabil. 2014;21(Suppl 1):S8–16.CrossRefGoogle Scholar
  67. 67.
    Wu T, Li JH, Song HX, Dong Y. Effectiveness of botulinum toxin for lower limbs spasticity after stroke: a systematic review and meta-analysis. Top Stroke Rehabil. 2016;23:217–23.CrossRefGoogle Scholar
  68. 68.
    Baker JA, Pereira G. The efficacy of Botulinum Toxin A for limb spasticity on improving activity restriction and quality of life: a systematic review and meta-analysis using the GRADE approach. Clin Rehabil. 2016;30:549–58.CrossRefGoogle Scholar
  69. 69.
    Gupta AD, Chu WH, Howell S, Chakraborty S, Koblar S, Visvanathan R, Cameron I, Wilson D. A systematic review: efficacy of botulinum toxin in walking and quality of life in post-stroke lower limb spasticity. Syst Rev. 2018;7:1.CrossRefGoogle Scholar
  70. 70.
    Stoquart GG, Detrembleur C, Palumbo S, Deltombe T, Lejeune TM. Effect of botulinum toxin injection in the rectus femoris on stiff-knee gait in people with stroke: a prospective observational study. Arch Phys Med Rehabil. 2008;89:56–61.CrossRefGoogle Scholar
  71. 71.
    Hutin E, Pradon D, Barbier F, Gracies JM, Bussel B, Roche N. Lower limb coordination in hemiparetic subjects: impact of botulinum toxin injections into rectus femoris. Neurorehabil Neural Repair. 2010;24:442–9.CrossRefGoogle Scholar
  72. 72.
    Robertson JV, Pradon D, Bensmail D, Fermanian C, Bussel B, Roche N. Relevance of botulinum toxin injection and nerve block of rectus femoris to kinematic and functional parameters of stiff knee gait in hemiplegic adults. Gait Posture. 2009;29:108–12.CrossRefGoogle Scholar
  73. 73.
    Chan J, Winter A, Palit M, Sturt R, Graaff SD, Holland AE. Are gait and mobility measures responsive to change following botulinum toxin injections in adults with lower limb spasticity? Disabil Rehabil. 2013;35:959–67.CrossRefGoogle Scholar
  74. 74.
    Baricich A, Picelli A, Molteni F, Guanziroli E, Santamato A. Post-stroke spasticity as a condition: a new perspective on patient evaluation. Funct Neurol. 2016;31:179–80.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Picelli A, Bonetti P, Fontana C, Barausse M, Dambruoso F, Gajofatto F, Tamburin S, Girardi P, Gimigliano R, Smania N. Accuracy of botulinum toxin type A injection into the gastrocnemius muscle of adults with spastic equinus: manual needle placement and electrical stimulation guidance compared using ultrasonography. J Rehabil Med. 2012;44:450–2.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Andrea Santamato
    • 1
    • 2
    Email author
  • Nicoletta Cinone
    • 1
  • Francesco Panza
    • 3
    • 4
    • 5
  • Sara Letizia
    • 1
  • Luigi Santoro
    • 1
  • Madia Lozupone
    • 3
  • Antonio Daniele
    • 6
    • 7
  • Alessandro Picelli
    • 8
    • 9
  • Alessio Baricich
    • 10
  • Domenico Intiso
    • 11
  • Maurizio Ranieri
    • 1
  1. 1.Physical Medicine and Rehabilitation Section, “OORR Hospital”University of FoggiaFoggiaItaly
  2. 2.“Fondazione Turati” Rehabilitation CentreViesteItaly
  3. 3.Neurodegenerative Disease Unit, Department of Basic Medical Sciences, Neuroscience and Sense OrgansUniversity of Bari “Aldo Moro”BariItaly
  4. 4.Department of Clinical Research in Neurology, Center for Neurodegenerative Diseases and the Aging BrainUniversity of Bari “Aldo Moro”TricaseItaly
  5. 5.Geriatric UnitFondazione IRCCS “Casa Sollievo della Sofferenza”San Giovanni RotondoItaly
  6. 6.Institute of NeurologyCatholic University of Sacred HeartRomeItaly
  7. 7.Fondazione Policlinico Universitario A. Gemelli IRCCSRomeItaly
  8. 8.Department of Neurosciences, Biomedicine and Movement Sciences, Neuromotor and Cognitive Rehabilitation Research CenterUniversity of VeronaVeronaItaly
  9. 9.Neurorehabilitation Unit, Department of NeurosciencesHospital Trust of VeronaVeronaItaly
  10. 10.Health Sciences DepartmentUniversità del Piemonte OrientaleNovaraItaly
  11. 11.Department of Neuro-Rehabilitation IRCCSCasa Sollievo della SofferenzaSan Giovanni RotondoItaly

Personalised recommendations